Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Peritoneal Neoplasms 1Endometrial Hyperplasia 1

Interventions

Megestrol Acetate 7Medroxyprogesterone Acetate 4Progestins 3Metformin 3Tirzepatide 2Progesterone 2Letrozole 2Hysteroscopy 2Blood Specimen Collection 2Biopsy 2Atorvastatin 2semaglutide 1ricin A-GnRH conjugate 1exemestane 1estradiol, norethindrone drug combination 1Tamoxifen 1Surveys and Questionnaires 1Sampling Studies 1Rosuvastatin Calcium 1Restraint, Physical 1Resistance Training 1Pterocarpus marsupium 1Pharmacogenomic Variants 1Observation 1Nutrition Assessment 1Magnetic Resonance Spectroscopy 1Levonorgestrel 1LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1Intrauterine Devices 1Immunohistochemistry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Hyperplasia × Pharmacogenomic Variants × Gynecologic × Clear all
NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 13 charts
Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡